BPC-157
Synthetic Pentadecapeptide - Synthetic pentadecapeptide studied for VEGF and growth-factor receptor signalling.
BPC-157 is a synthetic 15-residue peptide corresponding to a partial sequence identified in gastric juice. It is characterised in the preclinical literature for its interaction with the VEGF/VEGFR2 and nitric-oxide signalling axes, and for reported modulation of growth-hormone-receptor expression in cultured fibroblasts. Supplied as a characterised reference standard for in-vitro receptor and pathway work.
Interest in BPC-157 centres on VEGF/VEGFR2 and nitric-oxide pathway activity, where much of the literature comes from a single prolific group and is almost entirely rodent-based. In the laboratory it is handled as a stable lyophilised powder, reconstituted per the study protocol, and it is frequently paired with TB-500 in combination assay work.
BPC-157 specifications
- CAS number
- 137525-51-0
- Molecular formula
- C62H98N16O22
- Molecular weight
- 1419.53 g/mol
- Sequence
- Synthetic pentadecapeptide (15 amino acids)
- Presentation
- Lyophilised powder
- Documented purity
- 99.51% by HPLC
- Available sizes
- 10mg ($60), 20mg ($110)
- Archived COA lots
- 3
- Intended use
- Laboratory research use only. Not for human or veterinary use.
Studied pathways
- VEGF / VEGFR2 signalling - Studied for upregulation of vascular endothelial growth factor expression and downstream VEGFR2 pathway activity in cell and animal model systems.
- Growth-factor receptor expression - Reported to modulate growth-hormone-receptor expression in cultured tendon fibroblasts in preclinical assay systems.
- Nitric-oxide system - Described in the literature as interacting with the nitric-oxide synthase system across preclinical model systems.
Reported mechanisms in the literature
- VEGF / VEGFR2 signalling - Studied for upregulation of vascular endothelial growth factor expression and modulation of the nitric-oxide system in cell and animal model systems. (Sikirić et al.)
- Fibroblast receptor expression - Reported to raise growth-hormone-receptor expression in cultured tendon fibroblasts and to alter collagen-gene expression markers in preclinical assay systems. (Chang et al.)
- NOS system interaction - Described in the literature as interacting with the nitric-oxide synthase system across gastrointestinal and musculoskeletal model systems. (Sikirić et al.)
BPC-157 frequently asked questions
Is BPC-157 approved for human use?
No. BPC-157 is not approved by the FDA or any regulatory agency for human use and is not a drug, supplement, or medicine. The FDA has flagged it in compounded and supplement products. It is offered here strictly as a reference material for in-vitro laboratory research.
What does the research on BPC-157 show?
Published work is almost entirely preclinical (animal and cell studies). It has been characterised for VEGF and VEGFR2 pathway activity, nitric-oxide synthase system interaction, growth-hormone-receptor expression in cultured fibroblasts, and collagen-gene expression markers. No human clinical efficacy has been established.
How is BPC-157 handled in research?
It ships as a lyophilised powder and is reconstituted in the laboratory per the researcher's own protocol. Reconstitution volume, diluent and study design are determined by the qualified researcher; we supply the compound and its analytical data only.
Documented to 99.51% purity by HPLC · third-party COA every lot · from $60 · For laboratory research use only.
Related Regenerative & Repair compounds
- TB-500 - Thymosin β-4 fragment studied for actin regulation and tissue repair.
- BPC-157 / TB-500 - Co-formulated repair-research blend in a single vial.
- GHK-Cu - Copper tripeptide studied in skin-remodelling research.